Most AI leadership searches focus on technical capability. Medical device companies face a different challenge. The leaders they need must understand AI deployment and the regulatory requirements that determine whether a product reaches the market.
The conversation usually starts with a board describing what it wants: someone who has shipped AI into a clinical product and understands how regulated medical device organizations operate. That description sounds precise. In practice, that combination produces a candidate pool that is smaller than boards expect, and the ones that treat it like a conventional technology search tend to run into difficulty mid-process.
C&T's AI-Native Builder Report 2026 found demand for AI-native builders running 3.4 times available supply across all markets. In medical device, where regulatory submission experience and post-market monitoring expertise further narrow the pool, the imbalance becomes even more pronounced.
Why the Role Has Changed
Historically, many medical device CTO searches emphasized hardware, systems engineering, and device reliability. The differentiating capability was deep domain knowledge of the device itself, whether implantable cardiac, surgical robotics, imaging, or diagnostic equipment. AI existed at the edges of that work, in signal processing, anomaly detection, and workflow optimization inside the clinical environment.
That has shifted. The FDA authorized more than 1,250 AI-enabled medical devices as of July 2025, up from 950 in August 2024. In January 2025, the FDA published its draft guidance on AI-enabled device software functions, covering lifecycle management and marketing submission recommendations for adaptive algorithms. EU AI Act obligations for high-risk AI systems are also moving into force over the next regulatory cycle, with timelines still evolving for product-integrated systems such as medical devices. These regulatory developments are architectural requirements that have to be embedded into how a medical device engineering organization builds from the start.
The shift is especially visible in Software as a Medical Device (SaMD), where software itself performs medical functions without being tied to a specific hardware device. AI-enabled diagnostic, monitoring, and clinical decision support products increasingly fall into this category. For CTOs, that changes the job. The mandate now includes validation, regulatory submission, deployment, and ongoing performance monitoring in clinical environments.
In the searches we run, the CTO who built imaging algorithms without FDA submission experience and the one who has taken an adaptive AI system through a 510(k) clearance are rarely interchangeable, even when both appear qualified on paper.
What Is Happening in the Sector
The numbers coming out of medtech AI clearances tell a specific story about where the technology is and where regulation is heading.
Aidoc's CARE1 foundation model received FDA clearance in February 2025, the first foundation-model-powered clinical AI to do so. That clearance matters for hiring because it signals what the regulatory environment is now prepared to evaluate. Technology leaders who have taken a foundation model through FDA review have built organizational muscle that most medtech companies do not have yet.
Medtronic named Jim Peichel as its new Chief Technology Officer in November 2025. Peichel spent more than 25 years at Medtronic, most recently leading the Cardiac Implantables Technology Development Center. The internal promotion signals something specific: Medtronic chose depth in device engineering and regulatory environment over an external hire with broader AI credentials. That is one strategic posture. Many companies moving faster on AI product development are taking a different approach, bringing in technology leaders from adjacent sectors who combine AI deployment experience with the willingness to learn medical device regulatory requirements from the inside.
The incumbents are moving as well. Siemens Healthineers and GE HealthCare continue expanding AI across imaging and diagnostic workflows, treating AI as a product capability rather than an isolated feature. These initiatives require the same combination of engineering, regulatory, and clinical expertise that boards are increasingly searching for in technology leadership hires.
The FDA's 2026 Quality Management System Regulation update aligns US requirements with ISO 13485, adding another layer of governance that technology leaders in this sector have to understand as an operating constraint rather than a compliance checkbox.
The AI-Native Builder Profile in Medical Device
The AI-native builders who succeed in this sector share a specific characteristic that does not appear in most job descriptions. They treat regulatory validation as a technical discipline. Most candidates outside this sector treat it as a legal function. That distinction is visible in how they architect systems from the start.
In most technology sectors, the distinction between an AI-adapted engineer and an AI-native builder comes down to whether AI is architectural from the start or bolted on later. In medical device, that distinction exists but is secondary to another one: does this person understand that an adaptive algorithm deployed in a clinical device has to be validated under a framework that accounts for distribution shift, edge case performance, and post-market change management? Few engineers who have only shipped production AI in enterprise software environments have built that validation discipline.
The profiles that work in medical device AI leadership tend to come from a relatively narrow set of environments: medtech companies where AI was embedded into the product from the design phase, diagnostic imaging and pathology AI companies where the regulatory pathway was the primary engineering constraint, and adjacent regulated sectors such as aerospace or pharmaceuticals where safety-critical AI has been in production longer. The distinction between AI-adapted and AI-native builders, and what to look for when hiring this profile, is covered in C&T's AI-Native Builder Report 2026.
What I ask in every medical device AI leadership search that most job descriptions miss: has this person managed a post-market algorithm change under a Predetermined Change Control Plan?
The PCCP is a regulatory mechanism the FDA introduced to allow certain algorithm updates without a new submission. Understanding how to use it operationally, how to define the boundaries of acceptable change, and how to build the monitoring infrastructure that justifies it is a competency that separates candidates who have shipped adaptive AI in a regulated environment from those who have shipped AI and now need to learn the regulatory environment.
Few executives outside medical device AI have ever operated inside that framework. Boards frequently underestimate how uncommon that experience remains, which is one reason the qualified candidate pool is smaller than it appears on paper.
The Specific Roles Boards Are Filling
The medtech AI leadership search breaks into two distinct patterns depending on company stage and portfolio composition.
Large-cap medtech companies with established regulatory organizations are building out VP of AI Engineering and Chief Digital Officer roles where the mandate includes both product AI and operational AI. The product AI mandate covers embedded algorithms in devices, software as a medical device submissions, and the post-market surveillance infrastructure required to maintain clearance. The operational AI mandate covers clinical workflow optimization, manufacturing quality systems, and supply chain. These two mandates require different skills and are sometimes erroneously collapsed into a single hire.
Mid-market medtech companies and AI-native medical device startups are running a different search. They need a technology leader who can own the full AI product lifecycle from architecture through regulatory submission and post-market monitoring without the organizational support structure that large-cap companies provide. Butterfly Network is an example of the product profile: an AI-powered medical device company where technology leadership has to account for clinical reliability and FDA-regulated product development. These searches consistently take longer because the candidate has to be technically strong and experienced in regulatory submissions, and that combination narrows the available pool.
Unlike automotive or logistics, Forward Deployed Engineers in medical device organizations are rarely deployed against FDA-regulated device software. Their work is more commonly concentrated in operational AI initiatives, quality systems, clinical workflow automation, documentation processes, and internal productivity programs where the regulatory burden is lower. Some medtech companies are also hiring Forward Deployed Engineers to accelerate specific AI initiatives without opening a full CTO search.
What Boards Are Getting Wrong
The most common mistake boards make in this sector is writing a job description around technical AI credentials and treating regulatory experience as a nice-to-have. That approach produces candidates who are strong on the technical side and who will need 12 to 18 months to build the regulatory fluency the role actually requires. In a product cycle measured in years, that learning curve is expensive.
Healthcare technology leadership and medical device AI leadership are also frequently treated as interchangeable. Hospital IT systems, digital health platforms, and regulated AI-enabled medical products operate under different engineering and regulatory assumptions. The overlap exists, but the candidate pools are not the same.
Post-market monitoring experience is the requirement most consistently underweighted in search briefs. The strongest medical device AI leaders have built AI models and maintained their performance within FDA expectations after deployment. Both matter. Most candidates have done one.
The Market for Medical Device AI Leaders
As the qualified candidate pool has remained thin, compensation for medtech AI technology leadership has moved sharply. Organizations are competing for executives who combine clinical domain knowledge, production AI experience, and regulatory submission credentials, and the market is pricing that combination at a premium over general technology leadership.
At public companies with 10,000 to 50,000 employees, which covers most large-cap medtech organizations, an AI-Native CTO or CIO carries a base salary of $551,000 to $1.12 million with annualized equity reaching $7.475 million. VP of AI Engineering roles at that scale run $330,000 to $783,000 in base. SVP AI roles sit between $495,000 and $971,000. The full breakdown by company size is in C&T's 2026 AI Compensation Study.
The same dynamics increasingly affect medtech CIO searches as AI moves from back-office technology programs into regulated product environments. As AI becomes embedded in diagnostic, monitoring, and clinical software products, technology leadership decisions increasingly influence product strategy, regulatory execution, and post-market performance.
In the largest medtech organizations, these roles increasingly report directly to the CEO or Chief Product Officer rather than the Chief Medical Officer or Chief Scientific Officer.
The Signal That a Search Is Coming
When I watch public medtech company filings and earnings calls, a few patterns tend to precede a senior AI technology leadership change.
The most consistent pattern is when a company files for multiple AI-enabled device clearances within a short period but attributes the technical leadership generically rather than naming a specific executive owner. That attribution gap usually means the AI engineering organization is fragmented across business units without a unified technology leadership function.
Regulatory action is another signal. When the FDA issues a warning letter or requests additional post-market data on an AI-enabled device, the organizational response often requires technology leadership that can engage directly with the agency on the technical substance of the issue. Companies that lack that leadership tend to bring it in shortly after a regulatory event.
M&A tends to surface the gap most visibly. Medtech acquirers buying AI-native diagnostics or device software companies frequently discover that the acquired technology requires regulatory infrastructure the parent organization does not have. That capability gap tends to produce a technology leadership search within 12 to 18 months of close.
Conclusion
Medical device AI leadership searches are slower than boards expect and harder to staff than the job description implies.
The question that determines the outcome is who can own the model through validation, regulatory review, deployment, and post-market monitoring. The structure of that mandate matters more than the candidate evaluation that follows. Christian & Timbers works with boards and leadership teams to define those mandates before entering the market for talent.
Frequently Questions About Medical Device AI CTO Searches
- What background should a medical device AI CTO have?
The strongest candidates combine production AI deployment experience with direct involvement in FDA submission processes, specifically for adaptive or AI-enabled software. Clinical domain knowledge matters but is less important than regulatory fluency. A candidate who has taken an adaptive algorithm through a 510(k) or De Novo pathway and managed its post-market performance is a different hire than one who has shipped AI in an unregulated environment.
- Do medical device companies need a separate AI leader from their traditional CTO?
At companies where AI-enabled devices represent a significant portion of the portfolio, yes. The traditional medtech CTO profile is optimized for hardware systems, supplier management, and device reliability engineering. The AI product mandate requires a different technical background and a different relationship with the regulatory function. Combining both into a single CTO role usually means the company gets strength in one area and a learning curve in the other.
- How long does a medical device AI executive search take?
Longer than most boards expect. The combination of clinical domain knowledge, production AI experience, and regulatory submission credentials narrows the qualified pool. Searches for senior medtech AI technology leaders typically run 12 to 18 weeks from mandate definition to accepted offer. Compressing that timeline usually means compromising on one of the core requirements.
- Should medtech companies use Forward Deployed Engineers for regulated AI products?
Usually not. Forward Deployed Engineers can accelerate operational AI initiatives, workflow automation, and internal productivity programs. AI-enabled products that will pass through FDA review typically require longer-term ownership structures, regulatory accountability, and quality management processes that extend beyond the scope of a traditional FDE engagement.
- What should medtech companies look for when hiring Forward Deployed Engineers?
The strongest candidates understand more than software deployment. They can operate within clinical environments, work alongside regulatory and quality teams, and understand the documentation requirements that accompany healthcare technology programs. Access to frontier lab and Palantir alumni networks is valuable, but domain familiarity often determines whether an FDE succeeds inside a medical device organization.